acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition.
protein synthesis THIAZOLIDINEDIONES (TZDs) are synthetic ligands that activate the nuclear receptor peroxisome proliferator-activated receptor ␥ (PPAR␥; see Ref. 36) . These compounds are widely used in the treatment of type 2 diabetes mellitus (DM; see Refs. 32 and 33) . In addition to their beneficial effects on insulin resistance, growing evidence indicates that TZDs have an array of antiinflammatory effects in endothelial cells and macrophages, either by decreasing nuclear factor-B activity (7, 9) or by increasing endothelial nitric oxide synthase activity (8) , which may attenuate atherogenesis in patients with type 2 DM (4, 13, 14) . Furthermore, the TZDs inhibit both ANG II-induced cardiac hypertrophy in vitro and pressure overload-induced cardiac hypertrophy in vivo and improve cardiac function in these patients (2, 39) . TZDs also have antitumor activity in a wide variety of experimental cancer models, both in vitro and in vivo (26, 34) , by modulating the cell cycle, inducing cell differentiation and apoptosis, and inhibiting tumor angiogenesis. All of these effects are mediated by either PPAR␥-dependent or -independent signaling pathways, according to the TZD concentration and target cell type.
Protein synthesis has a pivotal role in various pathological states, including atherosclerosis, cardiac hypertrophy, and cancer (11, 12, 15) . The process of mRNA translation in mammalian cells is a major step in protein synthesis, and its control involves the regulation of multiple translation factors in the translation machinery. This is affected primarily by alterations in phosphorylation, which modulates their activities or capacities to interact with one another (29) . The protein kinase called "the mammalian target of rapamycin" (mTOR) is a convergence point for mRNA translation signaling pathways. It plays a critical role in regulating mRNA translation initiation by modulating its downstream effectors p70 ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1; see Refs. 29 and 37) . The activities of these translation regulators dramatically increase as a consequence of multisite phosphorylation during active cell growth. Furthermore, it has also been reported that genetic defects causing constitutive mTOR activation lead to the generation of tumors, and, in this context, inhibitors targeting mTOR have been tested as cancer therapy (6, 31) , suggesting a critical role for the mTOR signaling pathway in protein synthesis under pathological conditions. Besides the mTOR signaling pathway, the phosphorylation states of eIF2␣ and eukaryotic elongation factor 2 (eEF2) play important roles in mRNA translation initiation and elongation, respectively (21, 29) . However, the phosphorylation of these two translation factors is downregulated in active cell proliferation (5, 21) .
It seems very likely that TZDs inhibit protein synthesis by modulating the activity of multiple translation factors. However, the molecular mechanism for these inhibitory effects in endothelial cells remains unclear. In this study, we demonstrated that troglitazone, the first TZD synthesized, inhibited p70S6K activity via a protein phosphatase 2A (PP2A)-dependent mechanism, which led to the inhibition of protein synthesis in endothelial cells. Furthermore, we found that neither mTOR nor PPAR␥ was involved in this mechanism.
EXPERIMENTAL PROCEDURES
Materials. Troglitazone was obtained as a gift from Sankyo (Tokyo, Japan). Ciglitazone, pioglitazone, and rosiglitazone were purchased from Biomol Research Laboratories (Plymouth Meeting, PA), Calbiochem (Darmstadt, Germany), and Cayman Chemical (Ann Arbor, MI), respectively. Okadaic acid and rapamycin were obtained from Sigma Chemical (St. Louis, MO). GW-9662 was purchased from Tocris (Ellisville, MO). L- [3, 4, . Antibodies against the catalytic subunit of PP2A (PP2Ac) and hemagglutinin (HA) were purchased from Upstate Biotechnology (Lake Placid, NY) and Covance (Berkeley, CA), respectively. Collagenase (type 2) was purchased from Worthington Biochemical (Freehold, NJ). Minimal essential medium (MEM), DMEM, Dulbecco's PBS (DPBS), newborn calf serum (NCS), penicillin, streptomycin, L-glutamine, trypsin-EDTA solution, and the plastic labware used for cell culture were purchased from GIBCO-BRL (Gaithersburg, MD). Endothelial growth media-2 (EGM-2) and CS-C complete media were obtained from Cambrex Bio Science (Walkersville, MD) and Cell Systems (Kirkland, WA), respectively. All other chemicals were of the purest analytical grade.
Cell culture, drug treatment, and transfection. Bovine aortic endothelial cells (BAEC) were isolated and maintained in MEM supplemented with 5% NCS at 37°C under 5% CO 2 in air, as described previously (18) . Human umbilical vein endothelial cells (HUVEC) were purchased from Cambrex Bio Science and cultured in EGM-2 according to the manufacturer's instructions. Human brain microvascular endothelial cells (HBMEC) were obtained from Cell Systems and cultured in CS-C complete medium according to the supplier's instructions. Rat vascular smooth muscle cells (RVSMC) were a generous gift from Dr. Hyun-Young Park (National Institute of Health, Seoul, Korea), and Madin-Darby canine kidney (MDCK) cells and HeLa cells were kind gifts from Dr. Jae-Hwan Nam (Catholic University, Seoul, Korea). RVSMC, MDCK cells, and HeLa cells were maintained in DMEM supplemented with 10% FBS at 37°C under 5% CO 2 in air. When the cells had grown to between 60 and 80% confluence, they were maintained for the indicated times in either 0.5% NCS-MEM (for BAEC, HUVEC, and HBMEC) or serum-free DMEM (for RVSMC, MDCK cells, and HeLa cells) containing various concentrations of troglitazone or vehicle. In some experiments, BAEC were pretreated with the indicated drugs. For transfection experiments, cDNAs encoding wild-type p70S6K (19) were transfected in BAEC grown to 60% confluence in 60-mm culture dishes using lipofectin reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.
Measurement of protein synthesis. The cells were incubated in the appropriate culture medium containing L- [3, 4, H(N)]leucine (2.5 Ci/ml) in the absence or presence of various doses of TZDs for the indicated times at 37°C. In some experiments, BAEC were pretreated with the indicated drugs or transfected with cDNA encoding wild-type p70S6K. After incubation, the cells were washed three times with ice-cold DPBS, and their cellular proteins were precipitated with 10% TCA for 1 h at 4°C. The precipitates were washed two times with 95% ethanol, dissolved in 1 M NaOH, and then neutralized with 1 M HCl. The radioactivity of the incorporated L- [3, 4, H(N)]leucine was measured using liquid scintillation counting, normalized to the protein concentration, and used as an index of protein synthesis.
Lactate dehydrogenase release assay. Lactate dehydrogenase (LDH) was used as an index of cellular injury: the activity in the cultured medium represented LDH release from the BAEC treated with troglitazone or vehicle (DMSO) for the indicated times. For a negative control, cells were treated with only MEM supplemented with 0.5% NCS. A positive control was prepared by treating cells with 0.5% Tween 20. Cultured medium was collected, and the LDH release assay was performed using an LDH-LQ assay kit (ASAN Pharmaceutical, Seoul, Korea) according to the manufacturer's instructions.
Western blot analysis. For Western blot analysis, cells treated with TZDs in the absence or presence of various chemicals were washed with ice-cold DPBS and lysed in lysis buffer A [20 mM Tris ⅐ HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 mM ␤-glycerophosphate, 1 mM NaF, 1 mM Na 3VO4, and 1ϫ Protease Inhibitor Cocktail (Roche Molecular Biochemicals, Indianapolis, IN)]. Protein concentrations were determined using the BCA protein assay kit (Sigma). Equal quantities of protein (20 g) were separated on SDS-polyacrylamide gels under reducing conditions and then transferred to nitrocellulose membranes electrophoretically. The blots were then probed with the appropriate antibody directed against mTOR, p-mTORSer 2448 , p70S6K, p-p70S6K-Thr 389 , p-p70S6K-Thr 421 /Ser 424 , 4E-BP1, p-4E-BP1-Thr 70 , HA, or PP2Ac, followed by the corresponding secondary antibody, and finally developed using enhanced chemiluminescence reagents (Amersham Biosciences).
In vitro mTOR kinase assay. BAEC were treated with 20 M troglitazone or vehicle for 30 min, lysed in lysis buffer B [20 mM Tris ⅐ Cl (pH 7.4), 1% Nonidet P-40, 137 mM NaCl, 50 M EDTA, 1 mM PMSF, 1 mM NaF, 10 mM ␤-glycerophosphate, 1 mM Na 3VO4, and 1ϫ Protease Inhibitor Cocktail], and then centrifuged at 12,000 g for 10 min. The supernatant (450 g protein) was immunoprecipitated using 2 l of mTOR antibody. As a control experiment, 2 l of nonimmune serum (normal rabbit IgG) were used instead of mTOR antibody. The immunoprecipitates were washed three times with lysis buffer B and two times with kinase assay buffer [50 mM Tris ⅐ Cl (pH 7.5), 5 mM MgCl 2, 1 mM PMSF, 1 mM NaF, 10 mM ␤-glycerophosphate, 1 mM Na3VO4, and 1ϫ Protease Inhibitor Cocktail]. The immunoprecipitated mTOR was then resuspended in 25 l of kinase assay buffer, and the kinase assay was started by adding 1 Ci of [␥-32 P]ATP and 2 g of histone H1 as substrate. After a 20-min incubation at 30°C, the reaction was terminated by adding Laemmli sample buffer. The samples were boiled for 5 min and subjected to 12% SDS-PAGE, and the dried gel was exposed to X-ray films at Ϫ80°C. The mTOR kinase activity was quantified by measuring the densitometry of bands obtained using an image analysis program (ImageJ; NIH, Bethesda, MD).
Coimmunoprecipitation. After treatment with 20 M troglitazone or vehicle for 30 min, the BAEC were lysed with lysis buffer A and centrifuged at 12,000 g for 10 min. The supernatant (250 g protein) was precleared with 50 l of a 50% slurry of preequilibrated protein G-Sepharose at 4°C for 2 h. The precleared supernatant was incubated for 16 h at 4°C with 2 l of p70S6K antibody and then for 2 h at 4°C with 30 l of a 50% slurry of preequilibrated protein G-Sepharose. In a separate experiment, the precleared supernatant was also incubated with 2 l of PP2Ac antibody. The immunoprecipitates were washed thoroughly five times with lysis buffer A. The bound proteins were eluted with Laemmli sample buffer and subjected to Western blot analysis using the appropriate antibodies.
PP2A activity assay. The PP2A activity assay was carried out using the Serine/Threonine Phosphatase Assay System (Promega, Madison, WI) with minor modifications. BAEC were treated with 20 M troglitazone or vehicle for 30 min, lysed in lysis buffer B lacking serine/threonine phosphatase inhibitors such as NaF and ␤-glycerophosphate, and then centrifuged at 12,000 g for 10 min. The supernatant (500 g protein) was immunoprecipitated using 2 l of PP2Ac antibody. As a control experiment, 2 l of nonimmune serum (normal rabbit IgG) were used instead of PP2Ac antibody. The immunoprecipitates were washed three times with lysis buffer B lacking serine/ threonine phosphatase inhibitors and two times with PP2A assay buffer [50 mM imidazole (pH 7.2), 0.2 mM EGTA, 0.02% ␤-mercaptoethanol, 1 mM PMSF, and 1ϫ Protease Inhibitor Cocktail]. The PP2A enzyme reactions were started by adding PP2A assay buffer containing 100 M phosphopeptide, R-R-A-pT-V-A, as a phosphatase substrate to these immunoprecipitates. For a control experiment, PP2A assay buffer containing 100 nM okadaic acid was used for the enzyme reaction. After a 20-min incubation at 30°C, the reaction was terminated by adding 50 l of Molybdate Dye/Additive mixture. The cellular PP2A activity was quantified by measuring the optical density at 630 nm and normalized to the optical density obtained from the control experiment.
Statistical analysis. All results are expressed as means Ϯ SD, with n indicating the number of experiments. Statistical significance was determined using Student's t-test for two points. P Ͻ 0.05 was assumed statistically significant.
RESULTS

Troglitazone acutely inhibits protein synthesis in BAEC.
First, we tested whether troglitazone inhibited protein synthesis in BAEC. As shown in Fig. 1, A and B, troglitazone decreased protein synthesis in a time-and dose-dependent manner. In kinetic experiments, troglitazone (at 20 M) acutely (within 20 min) decreased protein synthesis (Fig. 1A) , and this inhibitory effect of troglitazone was prolonged for up to 3 h (data not shown). Protein synthesis was reduced ϳ60% with troglitazone treatment at 20 M for 30 min compared with the vehicle (DMSO)-treated control (Fig. 1B) . To test whether this troglitazone-induced inhibition of protein synthesis was the consequence of troglitazone-mediated cellular toxicity, we performed an LDH release assay. As shown in Fig. 1C , no alterations in cellular viability or integrity were found under our experimental conditions (20 M troglitazone treatment for 30 min). This was also true for longer (3h) troglitazone exposures (data not shown).
Troglitazone inhibits the activity of p70S6K independently of mTOR. Because the process of mRNA translation in mammalian cells is a major step in protein synthesis, and mTOR serves as a convergence point for mRNA translation, we next investigated whether troglitazone modulates the activity of multiple translation factors involved in the mTOR signaling pathway. As shown in Fig. 2A , we found a significant decrease in p70S6K phosphorylation at the earliest (10 min) time point, and this inhibitory effect was time dependent. Although we used antibodies raised against p-p70S6K-Thr 389 and p-p70S6K-Thr 421 /Ser 424 to measure p70S6K activity, the same results were obtained; therefore, only the data using antibody against p-p70S6K-Thr 421 /Ser 424 are presented here. In contrast with p70S6K phosphorylation, however, no alteration in the phosphorylation of mTOR, a well-known upstream molecule of p70S6K, was found under the same conditions. Similarly, we also found no alteration in the phosphorylation of 4E-BP1, a downstream substrate of mTOR related to mRNA translation initiation. These incompatible decreasing patterns were con- After treatment, the cells were washed, and the cellular proteins were precipitated with 10% TCA for 1 h at 4°C. The precipitates were washed with 95% ethanol, dissolved in 1 M NaOH, and then neutralized with 1 M HCl. The radioactivity of incorporated L- [3,4,5- 3 H (N)]leucine was measured and normalized to the protein concentration, and then expressed as counts/min (cpm; A) and the mean Ϯ SD radioactivity relative to the control (B). Lactate dehydrogenase (LDH) release was used to assess cellular toxicity on treatment with 20 M troglitazone (C). As a negative control, cells were treated with medium only. A positive control was prepared by treating cells with 0.5% Tween 20. Each bar represents the mean Ϯ SD enzymatic activity of the released LDH relative to that of the positive control (C). Differences were statistically significant at *P Ͻ 0.05 and **P Ͻ 0.01 (n ϭ 4 -6 experiments). firmed ( Fig. 2B) , suggesting that the mTOR-signaling pathway is not responsible for the acute inhibition of p70S6K activity by troglitazone. No alteration in mTOR activity under this experimental conditions was found using an in vitro mTOR kinase assay, as shown in Fig. 2C . To define the mechanism by which troglitazone acutely inhibits protein synthesis via the mTORindependent inhibition of p70S6K activity, all the subsequent experiments, unless otherwise stated, were performed with 20 M troglitazone treatment for 30 min. To further clarify the mTOR-independent modulation of p70S6K activity by troglitazone, we used rapamycin, a well-known mTOR inhibitor. As shown in Fig. 2D , pretreatment with rapamycin alone (500 nM) significantly decreased the phosphorylation of mTOR, 4E-BP1, and p70S6K. Furthermore, when cells were cotreated Fig. 2 . Troglitazone acutely inhibits the activity of p70 S6 kinase (p70S6K) independently of mammalian target of rapamycin (mTOR). BAEC were prepared as described in Fig. 1 . The cells were treated with 20 M troglitazone for the indicated times (A) and with various doses of troglitazone for 30 min (B). Control cells were treated with 0.05% DMSO only. After treatment, cell lysates were prepared, and equal amounts of cellular proteins were separated using SDS-PAGE and transferred onto nitrocellulose membranes electrophoretically. The blots are representative of those from at least four separate experiments. The phosphorylation levels of mTOR-Ser 2448 , 4E-binding protein 1 (4E-BP1)-Thr 70 , and p70S6K-Thr 421 /Ser 424 were measured using Western blotting with antibodies specific for the corresponding protein phosphorylated at specific sites. Total proteins were also detected by reprobing the nitrocellulose membranes with antibodies specific for corresponding proteins to monitor equal loading of the samples. Densitometry was used to quantify the phosphorylated bands relative to the total protein bands, and the graphs show the mean fold alterations below controls (ϮSD). For the in vitro mTOR kinase assay, BAEC was treated with 20 M troglitazone or vehicle for 30 min and lysed with buffer B, as described in EXPERIMENTAL PROCEDURES. After centrifugation, the supernatants were immunoprecipitated using mTOR antibody. For a control, normal rabbit IgG was used. With the use of immunoprecipitates, the kinase assay was started by adding 1 Ci of [␥-32 P]ATP and 2 g of histone H1 as substrate. After SDS-PAGE, the dried gel was exposed to X-ray films at Ϫ80°C. The mTOR kinase activity was quantified by measuring the densitometry of bands obtained using an image analysis program (C). In some experiments, cells were pretreated with 500 nM rapamycin for 30 min before treatment with 20 M troglitazone for 30 min. Control cells were treated with 0.05% DMSO plus 0.05% ethanol. Western blot analysis (D) and protein synthesis (E) were measured as described and are presented in Figs. 2A and 1 , respectively. Differences were statistically significant at *P Ͻ 0.05 and **P Ͻ 0.01. p, Phosphorylated; IP, immunoprecipitate; NS, not significant (n ϭ 4 -6).
with rapamycin and troglitazone, the inhibitory effect on p70S6K was additive. However, under this experimental condition, no further alterations in the phosphorylation of mTOR and 4E-BP1 were observed. These results indicate that rapamycin and troglitazone decrease p70S6K phosphorylation via separate signaling pathways, further showing that the inhibition of p70S6K phosphorylation by troglitazone is mediated by an mTOR-independent signaling pathway. Under our experimental condition, we also found that rapamycin and troglitazone each decreased protein synthesis (Fig. 2E) . Furthermore, when rapamycin and troglitazone were added together, the inhibitory effect on protein synthesis was almost additive, suggesting that there are two separate mechanisms for the rapamycin-and troglitazone-induced inhibition of protein synthesis in BAEC.
Ectopic expression of the p70S6K gene reverses the troglitazone-mediated inhibition of protein synthesis. Because the time-and dose-dependent decreases in p70S6K phosphorylation by troglitazone (Fig. 2 ) are fairly consistent with those of protein synthesis (Fig. 1) , we next examined whether the mTOR-independent inhibition of p70S6K activity by troglitazone plays a role in the troglitazone-mediated inhibition of protein synthesis. To this end, we transfected a HA-tagged wild-type p70S6K (WT-p70S6K) gene construct into BAEC. This was successful, as shown by the high expression of p70S6K protein and HA-tagged p70S6K in transfected cells (Fig. 3A) . Furthermore, overexpression of the WT-p70S6K gene significantly reversed the troglitazone-induced inhibition of protein synthesis (Fig. 3B) , suggesting a physiological role of p70S6K in this inhibitory signaling pathway. Our data shown in Figs. 1-3 demonstrate that troglitazone acutely inhibits protein synthesis at least in part by inhibiting p70S6K activity, which is mTOR independent.
PP2A mediates the troglitazone-induced inhibition of p70S6K phosphorylation and protein synthesis. PP2A is not only involved in regulating mTOR phosphorylation but also in the direct dephosphorylation or inactivation of p70S6K (17, 27) . Therefore, we examined whether PP2A plays roles in the troglitazone-induced inhibition of p70S6K phosphorylation and protein synthesis. As shown in Fig. 4A , the inhibition of PP2A activity by the addition of okadaic acid (100 nM) at a concentration specific for PP2A (10, 24) significantly reversed (ϳ80%) the repressed p70S6K phosphorylation by troglitazone, suggesting an important role of PP2A in this pathway. Although okadaic acid increased mTOR phosphorylation in the troglitazone-stimulated cells, the increased phosphorylation was also seen in basal cells, suggesting the involvement of PP2A in basal mTOR phosphorylation. Okadaic acid did not alter the phosphorylation of 4E-BP1. All these data suggest that the troglitazone-induced acute inhibition of p70S6K was mediated by PP2A, but not by mTOR. Next, we tested whether okadaic acid also reverses the inhibition of protein synthesis by troglitazone. As shown in Fig. 4B , okadaic acid significantly restored the inhibitory effect of troglitazone on protein synthesis, suggesting that the troglitazone-induced inhibition of p70S6K and protein synthesis is mediated at least in part by PP2A. Next, we investigated how PP2A exerts its role in mediating the troglitazone-induced inhibition of p70S6K activity. First, we tested whether troglitazone alters total cellular PP2A activity, but we failed to observe a significant alteration (Fig. 4C) . Because the PP2Ac has been shown to dephosphorylate and inactivate p70S6K via a direct interaction between PP2Ac and p70S6K (28), we tested whether troglitazone increases binding of PP2Ac with p70S6K without altering the total cellular PP2A activity. As shown in Fig. 4D , troglitazone significantly (ϳ2-fold) increased the interaction between PP2Ac and p70S6K as evidenced in coimmunoprecipitation experiments, suggesting that troglitazone inhibits p70S6K activity by inducing or stabilizing this PP2Ac/p70S6K complex.
Inhibition of p70S6K and protein synthesis by troglitazone does not require PPAR␥. It is still controversial whether the inhibitory effect of troglitazone on protein synthesis and cell proliferation is dependent on PPAR␥ (20) . In this study, we observed the inhibitory effect of p70S6K activity and protein synthesis at an earlier time point (10 -20 min) . Therefore, we hypothesized that a PPAR␥-mediated genomic action may not be responsible for the troglitazone-mediated inhibitory effects. To test this hypothesis, we used GW-9662 (5 M), a specific, irreversible PPAR␥ antagonist. Our results clearly showed that this antagonist had no effect on either the level of p70S6K Fig. 3 . Ectopic expression of the p70S6K gene reverses the troglitazonemediated inhibition of protein synthesis. BAEC, prepared as described in Fig.  1 and grown to 60% confluence, were transfected with cDNAs encoding wild-type (WT) p70S6K or with empty vector. The phosphorylation levels of mTOR-Ser 2448 and 4E-BP1-Thr 70 were measured using Western blotting (n ϭ 4 -6), as described in Fig. 2 . Overexpression of the WT-p70S6K gene after transfection was confirmed by detecting the expressed total p70S6K or hemagglutinin (HA)-tagged p70S6K (A). With the use of transfected cells, protein synthesis was measured (n ϭ 4 -6), as described in Fig. 1 (B) . Difference was statistically significant at *P Ͻ 0.05. phosphorylation (Fig. 5A ) or protein synthesis (Fig. 5B) , suggesting that the acute inhibition of protein synthesis by the troglitazone-induced p70S6K inhibition is mediated via a PPAR␥-independent signaling pathway.
Other TZDs have similar effects on the inhibition of protein synthesis and mTOR-independent p70S6K activity in BAEC. Next, we examined whether several different TZDs have the same effects as troglitazone. As shown in Fig. 6A , all the TZDs used in this study significantly and acutely (30 min) inhibited protein synthesis in BAEC. The order of efficacy for this inhibition was found to be troglitazone ϭ ciglitazone Ͼ pioglitazone Ͼ rosiglitazone. Furthermore, at the concentration that causes 50% inhibition of protein synthesis, the TZDs tested in this study all significantly inhibited the phosphorylation of p70S6K without altering phosphorylation in mTOR and 4E-BP1 (Fig. 6B) , suggesting that all of the TZDs tested share a common signaling pathway responsible for the acute inhibition of protein synthesis in BAEC.
The mTOR-independent inhibition of p70S6K phosphorylation by troglitazone is cell type-specific. We also tested whether the inhibitory effects of troglitazone are true for other cells. To this end, we used five more cell lines: two endothelial cell lines (HUVEC and HBMEC), two epithelial cell lines (MDCK and HeLa cells), and one vascular smooth muscle cell line (RVSMC). As shown in Fig. 7A , troglitazone (at 20 M for 30 min) inhibited protein synthesis in all of these cells, with different efficacies. Furthermore, at the dose at which troglitazone significantly inhibited protein synthesis, it also significantly inhibited mTOR-independent p70S6K phosphorylation in the two endothelial cell lines and MDCK cells (Fig. 7B) . In contrast, under the same experimental conditions, there was no inhibition of p70S6K phosphorylation in RVSMC or HeLa cells, suggesting that troglitazone mediates the mTOR-independent inhibition of p70S6K phosphorylation in a cell typedependent manner.
DISCUSSION
One important finding of this study is evidence that the inhibition of protein synthesis in response to acute troglitazone treatment is mediated, at least in part, by inhibiting p70S6K activity in endothelial cells. Furthermore, this inhibitory effect appears to be mTOR independent, as evidenced by our kinetic analysis and in vitro mTOR kinase assay. There are many reports that mTOR and its downstream effectors 4E-BP1, p70S6K, and eEF2 kinase play a key role in protein synthesis . Western blotting and a protein synthesis assay were performed (n ϭ 4 -6), and the data are presented as described in Figs. 2 and 1 , respectively. Total cellular PP2A activity was measured in the catalytic subunit of PP2A (PP2Ac) immunoprecipitated from cell lysates after treatment with 20 M troglitazone for 30 min, as described in EXPERIMENTAL PROCEDURES (C). Assay was started by adding PP2A assay buffer containing 100 M phosphopeptide, R-R-A-pT-V-A, as a phosphatase substrate in immunoprecipitated PP2Ac. For a control experiment, PP2A assay buffer containing 100 nM okadaic acid was also used. For the coimmunoprecipitation experiments, the cell lysates were immunoprecipitated (IP) using antibody against p70S6K or PP2Ac, as described in EXPERIMENTAL PROCEDURES (D). A control using nonimmune serum was also performed. The immunoprecipitates were then dissolved with Laemmli sample buffer. Equal amount of immunoprecipitates was confirmed on the same blot using the same antibodies used in immunoprecipitation. D, inset on left, shows the amount of PP2Ac on the same blot after short exposure. The bound proteins in the immunopreciptates were subjected to Western blot (WB) analysis using the respective antibodies. The blot shown is representative of at least four experiments. Each bar represents the relative association of p70S6K and PP2Ac in the respective immunoprecipitated complexes (ϮSD). Differences were statistically significant at *P Ͻ 0.05, #P Ͻ 0.05, and **P Ͻ 0.01; n ϭ 4 experiments. (21, 29) . Although mTOR tightly regulates all these effectors in most cases, there is an exception: the phosphorylation of eEF2 by energy depletion is mTOR independent (23) and occurs only at earlier times. Furthermore, it was also reported that tuberous sclerosis complex tumor suppressor genes TSC1 and TSC2 exert their effects on p70S6K inhibition via an mTOR-independent pathway (16, 30) . Here, we provide another case in which the acute inhibition of p70SK phosphorylation by troglitazone is also mediated by an mTOR-independent pathway. Note that the alteration in 4E-BP1 phosphorylation by troglitazone was tightly regulated by mTOR under these experimental conditions. The mTOR-independent inhibition of p70S6K activity is further supported by the use of rapamycin, a well-known mTOR inhibitor. As shown in Fig.  2D , rapamycin and troglitazone each appears to inhibit p70S6K phosphorylation independently. Because rapamycin specifically inhibits mTOR activity, the inhibition of p70S6K phosphorylation by rapamycin is likely caused by the decreased mTOR activity. This mTOR-dependent signaling pathway appears to be distinct from the mechanism by which troglitazone acutely inhibits p70S6K phosphorylation (Fig. 2,  A and B) , suggesting the existence of a novel regulatory mechanism. The mTOR-independent inhibition is also true for the inhibition of protein synthesis by troglitazone (Fig. 2E) .
Next, we found that acute treatment with troglitazone modulates PP2A activity toward p70S6K by inducing its interaction with p70S6K and vice versa, without altering the intracellular PP2A activity (Fig. 4D) . The interaction between PP2A and p70S6K has been observed previously (27) . Although the detailed mechanism is unknown, we speculate that troglitazone acutely induces endoplasmic reticulum (ER) stress, which causes PP2A to release from the ER and translocate to p70S6K and other unidentified components. This idea is supported by previous findings that PP2A functions as an ER stress-responsive phosphatase (35) and that troglitazone exerts ER stress (26) . Furthermore, our results showed that a PP2A inhibitor, okadaic acid, reversed p70S6K phosphorylation and protein synthesis only in troglitazone-treated cells, and not in basal cells (Fig. 4, A and B) . Therefore, the modulation of PP2A Other TZDs have similar effects on the inhibition of protein synthesis and mTOR-independent p70S6K activity in BAEC. BAEC were prepared as described in Fig. 1 . Cells were treated with various TZDs for 30 min (A). Protein synthesis was measured after cotreatment with L- [3, 4, H(N)]leucine (n ϭ 4), as described in Fig. 1 (A) . In some experiments, the cells were also treated for 30 min with TZDs at a concentration that causes 50% inhibition. The amount of phosphorylation of multiple translation factors was measured using Western blotting, as described in Fig. 2 , and the blots are representative of at least four separate experiments (B). activity on p70S6K may be one of the most important mechanisms underlying the inhibition of protein synthesis by acute troglitazone treatment. In this regard, it was previously reported that transforming growth factor-␤ (TGF-␤) induced G1 arrest by inhibiting p70S6K through the interaction with PP2A, which is released from the TGF-␤ receptor on receptor activation (28) .
Our data also demonstrate that okadaic acid partially, but not completely, reversed the inhibition of p70S6K phosphorylation and protein synthesis by troglitazone (Fig. 4) , suggesting that the troglitazone-induced inhibition of protein synthesis is mediated by at least two independent pathways: the PP2A-dependent inhibition of p70S6K phosphorylation and the PP2A-independent inhibition of other translation factors. This is Fig. 7 . mTOR-independent inhibition of p70S6K phosphorylation by troglitazone is cell type specific. All the cells were prepared as described in EXPERIMENTAL PROCEDURES. Cells were treated with 20 M troglitazone for 30 min. Protein synthesis was measured after cotreatment with L- [3, 4, H(N)]leucine (n ϭ 3), as described in Fig. 1A . In some experiments, all cells were treated with 20 M troglitazone for 30 min (B). Proteins after cell lysis were subjected to SDS-PAGE, as described in Fig. 2 . The blots are representative of at least four separate experiments. HBMEC, human brain microvascular endothelial cells; HUVEC, human umbilical vein endothelial cells; MDCK, Madin-Darby canine kidney; RVSMC, rat vascular smooth muscle cells. Differences were statistically significant at **P Ͻ 0.01, ##P Ͻ 0.01, † †P Ͻ 0.01, ‡ ‡P Ͻ 0.01, and § §P Ͻ 0.01. Fig. 8 . Schematic representation of the molecular mechanism underlying the PP2A-mediated inhibition of p70S6K and protein synthesis by troglitazone in endothelial cells. Troglitazone acutely decreased p70S6K activity by inducing its physical interaction with PP2Ac, which in turn inhibited protein synthesis. In this acute action of troglitazone, neither mTOR nor PPAR␥ was involved.
supported by the observation that overexpression of p70S6K in cells did not completely reverse the inhibition of protein synthesis by troglitazone (Fig. 3B) . In this regard, eIF2␣ and eEF2 are potential candidates. Previously, it was reported that ATP depletion acutely increased eEF2 phosphorylation (23) and that troglitazone acutely decreased intracellular ATP levels (38) . However, further studies are needed to clarify this issue, which is beyond the scope of this study.
It is still controversial whether the observed beneficial effects of troglitazone on atherosclerosis and cancer in vitro and in vivo necessarily require PPAR␥. Our data imply that the troglitazone-induced inhibition of p70S6K and protein synthesis is mediated by a PPAR␥-independent pathway because all the troglitazone-induced inhibitory effects were observed within 10 min (Figs. 1 and 2) . Our results obtained using GW-9662 also clearly show that the inhibitory effects of troglitazone on p70S6K phosphorylation and protein synthesis were not mediated by a genomic action of PPAR␥ as a transcription factor (Fig. 5) . These results support the previous report (26) showing that the antitumor activity of TZDs is not mediated via PPAR␥ and that the PPAR␥ gene itself is not a tumor-suppressor gene. Therefore, it is likely that other important PPAR␥-independent actions of TZDs will emerge.
We also found that the TZDs ciglitazone, pioglitazone, and rosiglitazone inhibited p70S6K activity and protein synthesis. However, their efficacies differed dramatically (Fig. 6 ). Although these drugs have the same structural backbone, several reports show that they have different effects on cellular proliferation and apoptosis, and in clinical use (3, 22) . At present, it is speculated that these different effects result from the structural differences in their side chains. However, further studies are needed to clarify the relationship between TZD structure and activity. Moreover, troglitazone inhibited mTORindependent p70S6K phosphorylation only in HUVEC, HB-MEC, and MDCK cells in addition to BAEC, whereas it increased p70S6K phosphorylation in RVSMC and HeLa cells (Fig. 7B ). Although these incompatible findings are not fully understood, they suggest that the p70S6K-mediated signaling pathway does not provide a general mechanism in all cell types for the acute inhibition of protein synthesis by troglitazone. Nonetheless, our data are the first to demonstrate that troglitazone (and perhaps other TZDs) inhibits protein synthesis via mTOR-independent p70S6K inhibition, at least in endothelial cells. Recently, two different effects of troglitazone on apoptosis were also reported that depended on cell type: it induced apoptosis in vascular smooth muscle cells (25) and inhibited apoptosis in endothelial cells (1) .
In conclusion, we demonstrated that a synthetic PPAR␥ ligand, troglitazone, acutely inhibits protein synthesis at least in part by inhibiting PP2A-dependent p70S6K phosphorylation in endothelial cells and that mTOR and PPAR␥ are not involved in this acute inhibitory effect (Fig. 8) . Our results are the first to demonstrate a new mechanism by which troglitazone acutely regulates translation factors and protein synthesis in endothelial cells.
